Double Dose ( DrugBank: - )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 38 | スティーヴンス・ジョンソン症候群 | 1 |
| 162 | 類天疱瘡（後天性表皮水疱症を含む。） | 1 |
38. スティーヴンス・ジョンソン症候群
臨床試験数 : 17 / 薬物数 : 29 - (DrugBank : 9) / 標的遺伝子数 : 15 - 標的パスウェイ数 : 101
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05520086 (ClinicalTrials.gov) | November 11, 2022 | 22/8/2022 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. | Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;Pemphigoid | Drug: Single Dose;Drug: Double Dose | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Effice Servicios Para la Investigacion S.L. | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | Spain |
162. 類天疱瘡（後天性表皮水疱症を含む。）
臨床試験数 : 90 / 薬物数 : 122 - (DrugBank : 47) / 標的遺伝子数 : 34 - 標的パスウェイ数 : 144
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05520086 (ClinicalTrials.gov) | November 11, 2022 | 22/8/2022 | Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. | Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. | Chronic Conjunctivitis;Stevens-Johnson Syndrome;Lyell Syndrome;Pemphigoid | Drug: Single Dose;Drug: Double Dose | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | Effice Servicios Para la Investigacion S.L. | Recruiting | 18 Years | N/A | All | 20 | Phase 1/Phase 2 | Spain |